Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: Correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy

Journal of Urology

Volumn 191, Issue 1, 2014, Pages 35-39

  North, Scott ^a   El Gehani, Faraj ^a   Santos, Cheryl ^a   Ghosh, Sunita ^a   Lai, Raymond ^a   Cass, Carol E ^a   Mackey, John R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

carcinoma; drug therapy; gemcitabine; neoadjuvant therapy; nucleoside transport proteins; transitional cell

Indexed keywords

CISPLATIN; DEOXYCYTIDINE KINASE; GEMCITABINE; NUCLEOSIDE TRANSPORTER; CARBOPLATIN;

ADULT; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; BLADDER SURGERY; BLADDER TRANSITIONAL CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; CANCER COMBINATION CHEMOTHERAPY; CYSTECTOMY; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; PATHOLOGY; TRANSURETHRAL RESECTION; TUMOR BIOPSY;

CARCINOMA; DCK; DEOXYCYTIDINE KINASE; DRUG THERAPY; GEMCITABINE; METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN; MVAC; NAC; NEOADJUVANT CHEMOTHERAPY; NEOADJUVANT THERAPY; NT; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDE TRANSPORTER; RADICAL CYSTECTOMY; RC; TRANSITIONAL CELL; TRANSURETHRAL RESECTION OF BLADDER TUMOR; TURBT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NUCLEOSIDE TRANSPORT PROTEINS; PLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; URINARY BLADDER NEOPLASMS;

EID: 84890120259     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.07.006     Document Type: Article

References (15)

1. World Health Organization. Available at www.who.int/en/. Accessed May 1, 2013.
2. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666
3. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859
4. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171
5. A. Sherif, L. Holmberg, and E. Rintala Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies Eur Urol 45 2004 297
6. P.U. Malmström, E. Rintala, and R. Wahlqvist Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group J Urol 155 1996 1903
7. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202
8. T.A. Splinter, H.I. Scher, and L. Denis The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group J Urol 147 1992 606
9. H. von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068
10. J.R. Mackey, S.A. Baldwin, and J.D. Young Nucleoside transport and its significance for anticancer drug resistance Drug Resist Updat 1 1998 310
11. J.R. Mackey, R.S. Mani, and M. Selner Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res 58 1998 4349
12. A.S. Fairey, S. Daneshmand, and D. Quinn Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California Urol Oncol 2012 Epub ahead of print
13. T. Koie, C. Ohyama, and Y. Hashimoto Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study Int J Clin Oncol 18 2013 724
14. O. Yeshchina, G.M. Badalato, and M.S. Wosnitzer Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder Urology 79 2012 384
15. K. Iwasaki, W. Obara, and Y. Kato Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer Jpn J Clin Oncol 43 2013 193